Cancer Family
Reproductive System Neoplasm
CI-CAN-00000338Explore in graph →
Non-malignant3,041 active trials38 approved drugs197 evidence items
- NCIt
- C3674
Loading cancer entity…
Cancer Family
CI-CAN-00000338Explore in graph →
Clinical trials
13,668 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT07109726 | A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations | recruiting | Phase 1 / Phase 2 | 205 | Terremoto Biosciences Inc.INDUSTRY | 4 | Sep 17, 2026 | clinicaltrials |
| NCT07576725 | Low Dose, Reduced Frequency Nivolumab for the Treatment of Unresectable or Metastatic Cancer, AFFORD IO Trial | not yet recruiting | Phase 2 | 50 | Fred Hutchinson Cancer CenterOTHER | 1 | Sep 17, 2026 | clinicaltrials |
| NCT03418480 | HARE-40: HPV Anti-CD40 RNA vaccinE(HARE-40) | completed | Phase 1 / Phase 2 | 32 | University of SouthamptonOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT03543189 | Combination of Nivolumab Immunotherapy With Radiation Therapy and Androgen Deprivation Therapy | completed | Phase 1 / Phase 2 | 44 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT04273061 | Investigating the Effects of Atezolizumab in People Whose Tumour DNA or RNA Indicates Possible Sensitivity(CAPTIV-8) | recruiting | Phase 2 | 50 | British Columbia Cancer AgencyOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06366347 | ALPINE: Maintenance Letrozole/Abemaciclib | recruiting | Phase 2 | 32 | Dana-Farber Cancer InstituteOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT06873555 | A Study of DC05F01 in Chinese Patients With Recurrent/Refractory Ovarian Cancer and Other Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 60 | Heronova PharmaceuticalsINDUSTRY | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07332455 | First-Time-in-Human Study of GSK5471713 in Adults With mCRPC | recruiting | Phase 1 / Phase 2 | 54 | GlaxoSmithKlineINDUSTRY | 8 | Sep 16, 2026 | clinicaltrials |
| NCT07549256 | Cannabidiol for Pain Relief of Patients With End-stage mCRPC(ProCan) | recruiting | Phase 2 | 58 | Regionshospital NordjyllandOTHER_GOV | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07608718 | Phase II Trial of Zanzalitinib in Patients With Metastatic Castration Resistant Prostate Cancer | not yet recruiting | Phase 2 | 19 | Pedro Barata, MD, MScOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT07718854 | Sacituzumab Tirumotecan +/- Pembrolizumab in I/O Exposed Metastatic or Recurrent Ovarian Clear Cell Cancer | recruiting | Phase 2 | 50 | Tufts Medical CenterOTHER | 1 | Sep 16, 2026 | clinicaltrials |
| NCT02522715 | Enzalutamide and Cabazitaxel in Treating Patients With Metastatic, Castration-Resistant Prostate Cancer | active not recruiting | Phase 1 / Phase 2 | 37 | OHSU Knight Cancer InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT04585750 | The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) | recruiting | Phase 1 / Phase 2 | 300 | PMV Pharmaceuticals, IncINDUSTRY | 9 | Sep 15, 2026 | clinicaltrials |
| NCT05670106 | A Study to Evaluate the Efficacy, Safety, Pharmacokinetics and Dosimetry of [177Lu]Lu-PSMA-617 in Chinese Adult Male Patients With Progressive PSMA-Positive mCRPC | completed | Phase 2 | 62 | Novartis PharmaceuticalsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05739981 | Phase II IMNN-001 (Also Known as GEN-1) on SLL With BEV and NACT, Newly Diagnosed Advanced Ovarian, Fallopian Tube or Primary Peritoneal Cancer(MRD) | recruiting | Phase 1 / Phase 2 | 30 | ImunonINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT05751941 | Study of Sipuleucel-T With or Without Continuing New Hormonal Agents in Metastatic Prostate Cancer | active not recruiting | Phase 2 | 26 | H. Lee Moffitt Cancer Center and Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06150417 | MDRT in Prostate Cancer Treated With Long-term Androgen Deprivation Therapy in the STAMPEDE Trial (METANOVA) | recruiting | Phase 2 | 200 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06412510 | Prehabilitation for EOC, Fallopian Tube, Primary Peritoneal Carcinoma and Pancreatic Cancer w/ NACT | active not recruiting | Phase 1 / Phase 2 | 1 | Case Comprehensive Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT06772441 | Artificial Intelligence Driven Personalisation of Radiotherapy and Concomitant Androgen Deprivation Therapy for Prostate Cancer Patients (the HypoPro Trial)(HypoPro) | recruiting | Phase 2 | 30 | German Oncology Center, CyprusOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07023627 | A Study of INCB123667 in Participants With Platinum-Resistant Ovarian Cancer With Cyclin E1 Overexpression(MAESTRA 1) | recruiting | Phase 2 | 160 | Incyte CorporationINDUSTRY | 8 | Sep 15, 2026 | clinicaltrials |
| NCT07303894 | A Study of Isoquercetin in People With Ovarian Cancer | recruiting | Phase 2 | 90 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07332000 | A Biomarker Study in Men With Localized Prostate Cancer Treated With Aglatimagene Besadenovec | recruiting | Phase 2 | 45 | Candel Therapeutics, Inc.INDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07341737 | SL-28 for Advanced Solid Tumours | recruiting | Phase 1 / Phase 2 | 60 | Second Life TherapeuticsINDUSTRY | 1 | Sep 15, 2026 | clinicaltrials |
| NCT07702292 | [68Ga]BED003 PET Imaging of Fibroblast Activation Protein in Selected Oncology Indications | recruiting | Phase 2 | 71 | Blue Earth DiagnosticsINDUSTRY | 2 | Sep 15, 2026 | clinicaltrials |
| NCT07820358 | Semaglutide, Weight Loss, and LNG-IUD for Conservative Treatment of Endometrial Atypical Hyperplasia and Grade 1 Endometrial Cancer(SWIFT) | not yet recruiting | Phase 2 | 48 | The Methodist Hospital Research InstituteOTHER | 1 | Sep 15, 2026 | clinicaltrials |
| NCT00525720 | Brachytherapy for Prostatic Carcinoma Patients | active not recruiting | Phase 2 | 300 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01012817 | Veliparib and Topotecan Hydrochloride in Treating Patients With Solid Tumors, Relapsed or Refractory Ovarian Cancer, or Primary Peritoneal Cancer | active not recruiting | Phase 1 / Phase 2 | 88 | National Cancer Institute (NCI)NIH | 1 | Sep 14, 2026 | clinicaltrials |
| NCT02703623 | Abiraterone Acetate, Prednisone, and Apalutamide With or Without Ipilimumab or Cabazitaxel and Carboplatin in Treating Patients With Metastatic Castration-Resistant Prostate Cancer | active not recruiting | Phase 2 | 196 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03042468 | Phase I Dose-escalation Study of Fractionated 177Lu-PSMA-617 for Progressive Metastatic CRPC | completed | Phase 1 / Phase 2 | 50 | Weill Medical College of Cornell UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT03070886 | Antiandrogen Therapy and Radiation Therapy With or Without Docetaxel in Treating Patients With Prostate Cancer That Has Been Removed by Surgery | active not recruiting | Phase 2 / Phase 3 | 612 | NRG OncologyOTHER | 3 | Sep 14, 2026 | clinicaltrials |
| NCT03074513 | Atezolizumab and Bevacizumab in Treating Patients With Rare Solid Tumors | active not recruiting | Phase 2 | 133 | M.D. Anderson Cancer CenterOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT04140526 | Safety, PK and Efficacy of ONC-392 in Monotherapy and in Combination of Anti-PD-1 in Advanced Solid Tumors and NSCLC(PRESERVE-001) | active not recruiting | Phase 1 / Phase 2 | 733 | OncoC4, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT04977453 | GI-101/GI-101A as a Single Agent or in Combination With Pembrolizumab or Lenvatinib in Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 317 | GI Innovation, Inc.INDUSTRY | 2 | Sep 14, 2026 | clinicaltrials |
| NCT05634499 | A Study of Giredestrant in Participants With Grade 1 Endometrial Cancer(EndomERA) | completed | Phase 2 | 33 | Hoffmann-La RocheINDUSTRY | 4 | Sep 14, 2026 | clinicaltrials |
| NCT06111781 | The SUGAR Study; SBRT and Relugolix) for Prostate Cancer | recruiting | Phase 2 | 60 | Yale UniversityOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT06303505 | FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma NSCLC(NAPISTAR1-01) | recruiting | Phase 1 / Phase 2 | 250 | Tubulis GmbHINDUSTRY | 8 | Sep 14, 2026 | clinicaltrials |
| NCT06433219 | Tuvusertib Combined With Niraparib or Lartesertib in Participants With Epithelial Ovarian Cancer (DDRiver EOC 302) | completed | Phase 2 | 63 | EMD Serono Research & Development Institute, Inc.INDUSTRY | 13 | Sep 14, 2026 | clinicaltrials |
| NCT06787612 | Investigation of Ubamatamab Combination Therapy in Adult Participants With Platinum-Resistant Ovarian Cancer | recruiting | Phase 2 | 297 | Regeneron PharmaceuticalsINDUSTRY | 5 | Sep 14, 2026 | clinicaltrials |
| NCT07808359 | Amivantamab in Patients With Metastatic/Recurrent Penile Squamous Cell Carcinoma(APOLO) | not yet recruiting | Phase 2 | 58 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 14, 2026 | clinicaltrials |
| NCT01807065 | Sipuleucel-T With or Without Radiation Therapy in Treating Patients With Hormone-Resistant Metastatic Prostate Cancer | completed | Phase 2 | 51 | City of Hope Medical CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT02960022 | A Study for Subjects With Prostate Cancer Who Previously Participated in an Enzalutamide Clinical Study | active not recruiting | Phase 2 | 900 | Astellas Pharma Global Development, Inc.INDUSTRY | 38 | Sep 11, 2026 | clinicaltrials |
| NCT05081609 | A Study to Investigate Safety and Tolerability of TransCon IL-2 β/γ Alone or in Combination With Pembrolizumab and/or TransCon TLR7/8 Agonist or Other Anticancer Therapies in Adult Participants With Locally Advanced or Metastatic Solid Tumor Malignancies(IL Believe) | active not recruiting | Phase 1 / Phase 2 | 320 | Ascendis Pharma Oncology Division A/SINDUSTRY | 10 | Sep 11, 2026 | clinicaltrials |
| NCT05123482 | A Phase I/IIa Study of AZD8205 Given Alone or Combined, in Participants With Advanced/Metastatic Solid Malignancies | recruiting | Phase 1 / Phase 2 | 460 | AstraZenecaINDUSTRY | 15 | Sep 11, 2026 | clinicaltrials |
| NCT05849298 | A Phase II Study of AAA617 Alone and AAA617 in Combination With ARPI in Patients With PSMA PET Scan Positive CRPC(PSMACare) | active not recruiting | Phase 2 | 49 | Novartis PharmaceuticalsINDUSTRY | 11 | Sep 11, 2026 | clinicaltrials |
| NCT06840002 | A Clinical Study of SHR-A1811 Combined With Chemotherapy for Platinum Sensitive Recurrent Ovarian Cancer | recruiting | Phase 1 / Phase 2 | 150 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07335796 | A Study of BMS986365 in Combination With Degarelix in People With Prostate Cancer | active not recruiting | Phase 2 | 7 | Memorial Sloan Kettering Cancer CenterOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07593079 | Prostate Specific Membrane Antigen (PSMA) Imaging for Detection of Residual and Metastatic Prostate Cancer | not yet recruiting | Phase 2 | 20 | Washington University School of MedicineOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815197 | Sacituzumab Tirumotecan as Second-Line Treatment for Penile Cancer(PERSEUS) | not yet recruiting | Phase 2 | 37 | Latin American Cooperative Oncology GroupOTHER | 1 | Sep 11, 2026 | clinicaltrials |
| NCT07815704 | Targeting Immune Modulation in High Grade Serous Carcinoma: Combined Effects of Chemotherapy and Atorvastatin | not yet recruiting | Phase 2 | 40 | University of Colorado, DenverOTHER | 1 | Sep 11, 2026 | clinicaltrials |
Data updated 13 days agoSource updated Sep 17, 2026source: clinicaltrials